| Market Cap | 147.11M | P/E | - | EPS this Y | 26.90% | Ern Qtrly Grth | - |
| Income | -44.9M | Forward P/E | -1.98 | EPS next Y | -26.30% | 50D Avg Chg | 6.00% |
| Sales | 7.26M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
| Dividend | N/A | Price/Book | 1.71 | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 2.00 | Quick Ratio | 0.87 | Shares Outstanding | 287.86M | 52W Low Chg | 30.00% |
| Insider Own | 1.41% | ROA | -49.82% | Shares Float | 283.91M | Beta | 3.73 |
| Inst Own | 23.52% | ROE | -114.42% | Shares Shorted/Prior | 50.90M/51.27M | Price | 0.57 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 7,785,711 | Target Price | 7.00 |
| Oper. Margin | -1,353.99% | Earnings Date | Nov 7 | Volume | 3,810,886 | Change | -5.14% |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
| Chardan Capital | Buy | May 15, 24 |
| HC Wainwright & Co. | Buy | May 15, 24 |
| Chardan Capital | Buy | Apr 22, 24 |
| HC Wainwright & Co. | Buy | Apr 3, 24 |
| HC Wainwright & Co. | Buy | Feb 22, 24 |
| HC Wainwright & Co. | Buy | Jan 24, 24 |
| Cantor Fitzgerald | Overweight | Aug 31, 23 |
| HC Wainwright & Co. | Buy | Aug 23, 23 |
| Chardan Capital | Buy | May 8, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Jan 17 | Sell | 1.28 | 100,000 | 128,000 | 2,227,950 | 01/19/23 |
| Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Jan 17 | Option | 0.51 | 100,000 | 51,000 | 2,327,950 | 01/19/23 |
| Kumar Ramesh | Director Director | Apr 18 | Option | 0.51 | 7,500 | 3,825 | 7,500 | 04/20/22 |
| Kumar Ramesh | Director Director | Apr 18 | Sell | 2.83 | 7,500 | 21,225 | 04/20/22 | |
| Zhang Junge | Director Director | Mar 03 | Option | 1.17 | 88,000 | 102,960 | 88,000 | 03/04/22 |
| Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Feb 14 | Option | 0.33 | 90,000 | 29,700 | 842,540 | 02/16/22 |
| Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Feb 14 | Sell | 3.74 | 90,000 | 336,600 | 752,540 | 02/16/22 |
| Potti Manish | Director Director | Dec 16 | Option | 1.17 | 45,000 | 52,650 | 45,000 | 12/17/21 |
| Kompella Uday | Director Director | Nov 01 | Sell | 15.03 | 50,000 | 751,500 | 154,416 | 11/03/21 |
| Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Nov 01 | Option | 0.51 | 115,367 | 58,837 | 521,367 | 11/03/21 |
| Musunuri Shankar | Chief Executive Offi.. Chief Executive Officer | Nov 01 | Sell | 14.15 | 115,367 | 1,632,443 | 406,000 | 11/03/21 |
| Kompella Uday | Director Director | Oct 18 | Sell | 8.72 | 201,731 | 1,759,094 | 277,685 | 10/20/21 |
| Kumar Ramesh | Director Director | Oct 18 | Option | 0.51 | 7,500 | 3,825 | 7,500 | 10/20/21 |
| Kumar Ramesh | Director Director | Oct 18 | Sell | 8.13 | 7,500 | 60,975 | 10/20/21 | |
| Kompella Uday | Director Director | Jul 30 | Option | 1.83 | 10,000 | 18,300 | 560,674 | 07/30/21 |